智通财经APP获悉,四环医药(00460)再涨超3%,截至发稿,涨3.28%,报0.63港元,成交额914.2万港元。
消息面上,近日,四环医药公布2024年业绩,总收益约为人民币19.01亿元(单位下同),同比上升约2.2%。毛利约为12.42亿元,整体研究及开发开支约为4.74亿元,同比下降18.0%。年内经营活动的现金流量流入净额约为2.44亿元。
其中,来自医美业务的销售收益约为7.44亿元,同比上升约65.4%,主要由于年内产品获得市场的高度认可,从而推动医美销售收入大幅增长,叠加新产品销售带来的新增收入。来自创新药及其他药品的收益约为5760万元,同比上升约388.1%。主要由于轩竹生物自研的一类新药安奈拉唑钠于2023年下半年获批上市并开始产生收入。以上销售收益的变动趋势符合国内当前的“创新驱动,腾笼换鸟”的行业政策趋势。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.